Blood test for gene changes in advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hormone receptor-positive (ER+ and/or PgR+) breast cancer that is HER2-negative.
- Your breast cancer has spread to other parts of the body or is advanced (stage IV).
- You have not yet started treatment for advanced disease, or your cancer has gotten worse after treatment with a CDK4/6 inhibitor.
- You are able to give written informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help doctors see how well treatment is working for advanced breast cancer that has stopped responding. It may help guide future care.
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
This study looks at a blood test that measures certain markers on cancer cells (CTCs) and genetic material in the blood (cfDNA/RNA) in women with metastatic breast cancer. It aims to better understand the cancer and guide treatment decisions.
This trial checks whether routine blood tests can detect a specific genetic change (ESR1 mutation) that may make hormone therapy less effective over time. It is for people whose cancer is stable while taking a standard first-line treatment, and the results may help guide future care.
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Hear when a new Breast Cancer, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.